--- title: "Bio-Techne: Business Model" description: "Bio-Techne revenue by business segment and geography from its fiscal 2025 Form 10-K, with each part's share, growth and profitability explained." canonical: https://www.getswoopr.com/stocks/companies/bio-techne/business-model/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Bio-Techne: Business Model & Revenue Engine ## Direct Answer Bio-Techne reports revenue across 2 business segments in its fiscal 2025 Form 10-K. Protein Sciences is the largest, with $870 million of revenue (71% of the total), followed by Diagnostics and Spatial Biology at $346 million (28%). 56% of revenue came from the United States. ## How Does Bio-Techne Make Money? Protein Sciences supplies 71% of revenue, so Bio-Techne's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, Diagnostics and Spatial Biology grew fastest (+6.1%) and Protein Sciences slowest (+4.7%), so the revenue mix tilts toward Diagnostics and Spatial Biology while that gap lasts. | Segment | FY2025 revenue | FY2024 revenue | Share of revenue | Change | | --- | --- | --- | --- | --- | | Protein Sciences | $870 million | $831 million | 71.4% | 4.7% | | Diagnostics and Spatial Biology | $346 million | $326 million | 28.4% | 6.1% | ![Bar chart of Bio-Techne revenue by segment for fiscal 2025: Protein Sciences 71.4%, Diagnostics and Spatial Biology 28.4%.](https://www.getswoopr.com/images/charts/bio-techne-business-model-segment-mix.webp) *Bio-Techne revenue by segment as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.* ## Which Bio-Techne Segments Earn the Most? | Segment | FY2025 segment operating income | Segment margin | | --- | --- | --- | | Protein Sciences | $370 million | 42.6% | | Diagnostics and Spatial Biology | $21 million | 6.2% | Segment operating income is the profit measure Bio-Techne reports to its chief operating decision maker for each segment. It usually leaves out corporate costs that are not allocated to a segment, so the segments usually add up to more than consolidated operating income, and margins are comparable within Bio-Techne more safely than against another company. ## What Does Bio-Techne Sell? Bio-Techne also breaks revenue down by product and service line, which shows what customers pay for rather than how management organizes the business. | Product or service | FY2025 revenue | FY2024 revenue | Share of revenue | Change | | --- | --- | --- | --- | --- | | Consumables | $972 million | $928 million | 79.7% | 4.8% | | Instruments | $112 million | $108 million | 9.2% | 3.5% | | Service | $112 million | $99 million | 9.1% | 12.4% | | Royalty | $24 million | $23 million | 1.9% | 1.5% | ## Where Does Bio-Techne's Revenue Come From? Regions follow the definitions in the filing; most companies assign revenue by customer location. | Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change | | --- | --- | --- | --- | --- | | United States | $683 million | $658 million | 56.0% | 3.9% | | EMEA Excluding UK | $266 million | $241 million | 21.8% | 10.3% | | China | $100 million | $99 million | 8.2% | 1.0% | | APAC Excluding Greater China | $77 million | $74 million | 6.3% | 4.5% | | United Kingdom | $55 million | $50 million | 4.5% | 9.6% | | Rest of World | $38 million | $36 million | 3.1% | 2.9% | ## What the Segment Figures Do Not Show The rows above add up to 100% of Bio-Techne's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin. ## Where These Numbers Come From Every figure on this page is a value Bio-Techne reported in the segment note and revenue disclosures of its Form 10-K filed August 22, 2025 (accession 0001558370-25-011716), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading. Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What are Bio-Techne's business segments? In its fiscal 2025 Form 10-K, Bio-Techne reports revenue for Protein Sciences and Diagnostics and Spatial Biology. ### Which part of Bio-Techne brings in the most revenue? Protein Sciences, with $870 million of revenue in fiscal 2025, or 71% of the total. ### How much of Bio-Techne's revenue comes from outside the United States? 44% in fiscal 2025, by the geographic breakdown Bio-Techne reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies. ## References - [SEC EDGAR: BIO-TECHNE Corp Form 10-K filed August 24, 2026](https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm) - [SEC EDGAR: BIO-TECHNE Corp annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=842023&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) - [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets) ## Related Pages - [Bio-Techne company dossier](https://www.getswoopr.com/stocks/companies/bio-techne/) - [Bio-Techne financial metrics](https://www.getswoopr.com/stocks/companies/bio-techne/metrics/) - [Bio-Techne financial risk indicators](https://www.getswoopr.com/stocks/companies/bio-techne/risks/) - [Bio-Techne peer comparison](https://www.getswoopr.com/stocks/companies/bio-techne/competitors/) - [Bio-Techne business model and revenue mix](https://www.getswoopr.com/stocks/companies/bio-techne/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).